Galapagos optimistic on filgotinib beyond RA, despite two misses

Galapagos remained positive on filgotinib’s development in autoimmune diseases outside of rheumatoid arthritis, despite a pair of failures in cutaneous lupus and Sjögren syndrome.

“I’m personally excited about these results,” Walid Abi-Saab, CMO of Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), said on the company’s earnings call Friday. “I think these support taking the next step and further evaluating Phase II.” ...